Loading
Talazoparib helped some people with advanced cancers carrying tumour-only BRCA mutations. The study was small and included several cancer types.
Phase 2 molecular basket, median four prior lines of therapy. Cohorts included somatic BRCA1/2, other homologous-recombination repair genes, PTEN and germline BRCA1/2 in cancers outside breast/ovarian indications. Clinical benefit included response or stable disease lasting at least 24 weeks.
Mixed, heavily pretreated cancers and no control arm; cannot compare its ORR directly with olaparib trials or establish postoperative benefit.
Shares Talazoparib, PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares Talazoparib, PARP, Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Breast cancer (all types).
Shares PARP, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/